Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bluetooth

- PMLiVE

Novo Nordisk and Evotec inks drug development deal

Will develop drugs for obesity and diabetes

- PMLiVE

Novo spends $800m to buy biotech and ‘glucose responsive insulin’ tech

Ziylo could help it stay ahead in key insulin franchise

- PMLiVE

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Firm relying on launch success in pressured US market

- PMLiVE

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

It could be the first new drug in 15 years to slow kidney damage development

Research Partnership launches new patient Living with Diabetes (LATAM) 2018 report

Living with Diabetes is a study conducted amongst approximately 200 Type 2 (T2D) diabetes patients in Brazil and Mexico. The report will consist of quantitative 30-minute online and qualitative telephone...

Research Partnership

- PMLiVE

Mylan sees the UK paving the way for an insulin game changer

As biosimilars surge into the insulin market, governments  are urged to seize ‘the opportunity of the century’

- PMLiVE

Novo’s diabetes pill defeats Merck’s Januvia in trial

Oral semaglutide also outshines its best-selling diabetes injectable Victoza

Global mHealth market predicted to reach $58.8bn by 2020

And digital therapeutics could rival mainstream pharmaceutical products, according to a report

- PMLiVE

FDA starts review of Sanofi’s oral type 1 diabetes drug

The US regulator has started its review of Sanofi and Lexicon Pharma’s sotagliflozin for type 1 diabetes, which the firms say could have blockbuster potential.Sotagliflozin – which has the proposed...

- PMLiVE

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Insulin specialist bounces back with encouraging signs from Ozempic launch

Lilly appoints Maura Dickler as VP of late phase oncology development

She will join the pharma firm from the Memorial Sloan Kettering Cancer Center

- PMLiVE

Novo’s oral semaglutide ‘safe and well-tolerated’

Releases first phase III data on the new version of its diabetes treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links